EOLO PHARMA today announced that it has dosed the first subjects in Phase 1 clinical trials of MVD1, designed to prevent and treat obesity and its cardiometabolic complications. “Initiating clinical studies for MVD1, Eolo’s lead compound targeting obesity and its associated cardiometabolic complications, is a significant milestone for the company,” said María Pía Garat, cofounder and CEO of EOLO
MVD1-AU-001 (ACTRN12622001519741) is the Phase 1, randomized, double-blind, placebo-controlled, first in human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of MVD1 in healthy adult volunteers’ study in up to 24 normal healthy volunteers (NHV) and up to 24 volunteer with over-weight or obesity volunteers. The single ascending dose portion of the study includes 4 sequentially enrolled NHV cohorts with escalating single-dose levels.
About EOLO Pharma.
EOLO PHARMA develops small molecules aimed to treat chronic metabolic diseases, such as obesity, type II diabetes and cardiovascular diseases. However, its portfolio of molecules goes beyond that. EOLO’s technology has proved to be effective for several diseases that involve low-grade chronic inflammation. As such, EOLO’s team of world class scientists, in cooperation with the Institut Pasteur de Montevideo and Universidad de La República, is currently also developing small molecules that are effective in preclinical models of neurodegenerative and autoimmune diseases. As a result of its innovative and disruptive approach to drug design, EOLO has a portfolio of protected small molecules with the potential of targeting metabolic, aging and immune diseases.